Pharmacokienetic studies on Docetaxel in breast cancer Patients

Pharmacokienetic studies on Docetaxel in breast cancer Patients
Role of Cytochrome 3A4 in Relation to Activity
 Paperback
Print on Demand | Lieferzeit: Print on Demand - Lieferbar innerhalb von 3-5 Werktagen I

55,90 €* Paperback

Alle Preise inkl. MwSt. | Versandkostenfrei
Artikel-Nr:
9783330971547
Veröffentl:
2017
Einband:
Paperback
Erscheinungsdatum:
07.06.2017
Seiten:
140
Autor:
Mervat Omran
Gewicht:
227 g
Format:
220x150x9 mm
Sprache:
Englisch
Beschreibung:

Mervat Omran is a Pharmacology lecturer in National Cancer Institute (NCI), Cairo University. She got her bachelor and Master degree from faculty of Pharmacy, Ain Shams University, and PhD from NCI. Her researches focused in pharmacokinetics of different chemotherapy drugs especially in breast and hematological cancer.
Worldwide, breast cancer is the leading type of cancer in women. Among Egyptian women breast cancer showed the highest frequencies among all cancers. Docetaxel (DCX) is one of the chemotherapy medication used to treat breast cancer which mainly metabolized in the liver by cytochrome3A4. The present study was conducted to study pharmacokinetic and pharmacodynamic properties of DCX in Egyptian breast cancer patients and the interpatient variability of cytochrome3A4 activity, as estimated using urinary metabolites of exogenous cortisol. The practical work was take place in NCI, Cairo University, Egypt.

Kunden Rezensionen

Zu diesem Artikel ist noch keine Rezension vorhanden.
Helfen sie anderen Besuchern und verfassen Sie selbst eine Rezension.